Cardiac Rhythm Disease Management (CRDM) Business Overview
FY2008 Revenue
CRDM accounted for $4.9 billion, or 37%, of Medtronic's $13.5 billion in revenue in FY2008.
CRDM is the oldest and largest of Medtronic's business units. Our work in heart rhythm therapies dates back to 1957, when co-founder Earl Bakken developed the first wearable heart pacemaker to treat abnormally slow heart rates. Since then, we've expanded our expertise in electrical stimulation to treat other cardiac rhythm diseases. We've also moved into more overall disease management by adding diagnostic and monitoring capabilities to many of our devices.
Today, CRDM's primary product lines are:
Our latest ICDs and CRT-Ds, under the Vision 3D™ portfolio, automatically and wirelessly transmit information through a home monitor from a patient's device to a secure website accessible from the physician's office. This makes it easier for physicians to manage their patients' heart failure long-term.
- Implantable pacemakers1 and accessories for treating hearts that beat too slowly. We also provide a unique, insertable diagnostic monitor2 that can help physicians determine if unexplained fainting may be the result of an abnormally slow heart rhythm.
- Implantable cardioverter-defibrillators (ICDs) for monitoring and correcting heart rates that are dangerously out of rhythm. Our latest ICDs3 include a feature called OptiVol Fluid Monitoring, which allows physicians to continually track their patients' fluid status using intrathoracic impedance (changes in the fluid flow). OptiVol also provides trending data so physicians can adjust medical treatment for patients at risk of acute decompensated heart failure.
- Implantable cardiac resynchronization therapy devices (CRTs),4 often combined with defibrillators (CRT-Ds), that synchronize the beating of the left and right heart chambers to optimize pumping capability for persons with heart failure.
- Monitoring systems that link wearers of implantable devices with their physicians via the Internet. This allows physicians to perform a complete analysis of all the data stored in a patient's device, similar to what would be viewed in an in-office visit. For some people, this may mean fewer in-office visits, and less time traveling to and from the clinic. Currently, more than 250,000 patients at nearly 2400 clinics in 20 countries are followed remotely using the Medtronic CareLink Network.5 CareLink is also available for patients who use Medtronic diabetes devices.
References
- Important Safety Information for the Adapta® Pacing System
- Important Safety Information for Reveal® Insertable Cardiac Monitor
- Important Safety Information for Virtuoso® ICD
- Important Safety Information for Concerto® CRT-D
- Important Safety Information for Medtronic CareLink® Network
- Print Page
- E-mail Page
- A
- A
- A Text Size
Additional information
NYSE (MDT)
Enduring Partnerships
Our history of working closely with cardiologists and other medical professionals began with our very first device.